A new treatment method, known as mRNA vaccines, has emerged with the goal of generating spike proteins, mimicking COVID-19 virus attacks. This approach aims to trigger the body’s natural defense mechanism by creating antibodies against future viral infections.
However, a critical review of literature raises questions about the existence of claimed mRNA in these vaccines. Instead, it suggests that isolate/culture-based substances are utilized, potentially leading to significant adverse effects.
Scientifically, the efficacy of a vaccine involves several steps: (1) mRNA in lipid- or nanoparticle-wrapped vials; (2) release of mRNA within cells; (3) production of spike proteins (s-proteins); (4) activation of the immune system to generate antibodies; (5) effective recognition and neutralization of the virus.
All these steps pivot on the initial presence of mRNA (the first step).
In pharmaceutical terms, obtaining the active ingredient, in this case, mRNA, is pivotal. This substance should ideally be sourced from a certified third-party supplier, ensuring both identification and purity.
Yet, information about the nature and purity of COVID-19 mRNA remains proprietary. This necessitates reliance on general knowledge about the vaccine’s composition and the processes involved.
The production process involves a fermentation procedure with bacteria to yield mRNA, which is then extracted. The subsequent steps include chemical reactions, purification, and formulation.
It is crucial to distinguish between mRNA and the vaccine itself. While mRNA is the active ingredient, the vaccine is a formulated product comprising various components.
Referring to the final step as “formulation” implies that mRNA may not have been produced independently, but is assumed to be present. This raises concerns regarding the actual isolation and purity of the mRNA compound.
The absence of a test for monitoring mRNA production without a pure reference standard further complicates matters. This calls into question the scientific validity of mRNA production.
Recent findings regarding DNA contaminants in vaccines underscore the need for thorough investigations. The presence of bacterial particles used in mRNA production may explain this contamination, potentially leading to unintended consequences.
In light of these concerns, a careful reevaluation of the vaccination process is warranted, with a focus on potential bacterial contamination and associated infections. Immediate action may be needed to safeguard public health.
For more detailed insights on this topic, refer to the author’s work, which draws from over 35 years of experience in substance isolation, characterization, and analytical testing during their tenure as a Research Scientist at Health Canada.